Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is
FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer
radiation treatment that gives fewer, but higher doses of radiation than standard radiation.
With SBRT, radiation is focused toward the cancer and away from normal surrounding lung
tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more
effective in activating the immune system. SBRT is a standard FDA approved treatment for
early stage (stage 1) lung cancer and is investigational in patients such as yourself with
stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study
will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.